| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
IC50: antiplasmodial[1]
Plasmodium falciparum. Myrrhone has antiplasmodial effects against the malaria parasite. Its molecular target is not well-characterized, but it is a terpenoid compound with activity against the parasite. |
|---|---|
| ln Vitro |
Myrrhone has an IC50 of 4.7 μg/ml against Plasmodium falciparum. Additionally, 29 μg/ml of the substance is cytotoxic to L6 rat skeletal myoblasts[1].
Myrrhone has an IC50 of 4.7 µg/ml against Plasmodium falciparum. It has cytotoxicity against L6 rat skeletal myoblasts with an IC50 of 29 µg/ml. This indicates a selectivity index of approximately 6. |
| ln Vivo |
In vivo activity data for Myrrhone is not extensively detailed in the literature. As an antiplasmodial agent, it is expected to show efficacy in mouse models of malaria. Its cytotoxicity against mammalian cells suggests it may have a narrow therapeutic window.
|
| Enzyme Assay |
In vitro assays for antiplasmodial activity are performed using P. falciparum cultures. Parasite growth is measured by [3H]-hypoxanthine incorporation or by microscopic counting of parasitemia. The compound is serially diluted, and IC50 values are calculated.
|
| Cell Assay |
Cytotoxicity is assessed using L6 rat skeletal myoblasts or other mammalian cell lines. Cells are treated with Myrrhone, and cell viability is measured using MTT or Alamar Blue assays. The selectivity index is calculated as the ratio of cytotoxicity IC50 to antiplasmodial IC50.
|
| Animal Protocol |
In vivo efficacy studies are performed in mouse models of malaria (e.g., P. berghei-infected mice). Myrrhone is administered orally or intraperitoneally. Parasitemia is monitored by blood smear microscopy. Survival rates are recorded. Pharmacokinetic and toxicity studies are conducted in parallel.
|
| ADME/Pharmacokinetics |
Myrrhone has a molecular weight of 228.29 and a molecular formula of C15H16O2. It is a furanosesquiterpenoid compound. Detailed pharmacokinetic parameters such as oral bioavailability and half-life are available from specialized databases. It is typically stored at -20°C.
|
| Toxicity/Toxicokinetics |
Myrrhone has cytotoxicity against L6 rat skeletal myoblasts with an IC50 of 29 µg/ml. This suggests it may have significant toxicity, which could limit its therapeutic potential. Further toxicological studies are needed to assess its safety profile.
|
| References | |
| Additional Infomation |
According to reports, myrrh contains (8R)-1,5,8-trimethyl-8,9-dihydro-7H-benzo[e][1]benzofuran-6-one, and there is relevant data.
Myrrhone is a research-grade natural product. It is used as a tool to study antiplasmodial activity and as a lead compound for anti-malarial drug discovery. It is not approved for clinical use. Its molecular formula is C15H16O2 and its molecular weight is 228.29. |
| Molecular Formula |
C15H16O2
|
|---|---|
| Molecular Weight |
228.29
|
| Exact Mass |
228.115
|
| CAS # |
183551-83-9
|
| PubChem CID |
134715234
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.814
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
325
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([H])=C(C([H])([H])[H])C2=C1C([H])=C(C([H])([H])[H])C1C(C([H])([H])[C@@]([H])(C([H])([H])[H])C([H])([H])C=12)=O
|
| InChi Key |
SHEOKDCVBGTHJG-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C15H16O2/c1-8-4-11-14(12(16)5-8)9(2)6-13-15(11)10(3)7-17-13/h6-8H,4-5H2,1-3H3/t8-/m1/s1
|
| Chemical Name |
(8R)-1,5,8-trimethyl-8,9-dihydro-7H-benzo[e][1]benzofuran-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3804 mL | 21.9020 mL | 43.8039 mL | |
| 5 mM | 0.8761 mL | 4.3804 mL | 8.7608 mL | |
| 10 mM | 0.4380 mL | 2.1902 mL | 4.3804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
